News Column

Recent Research from Molecular Pharmacology and Chemistry Program Highlight Findings in Cell Therapy (CD28z CARs and Armored CARs)

July 21, 2014

By a News Reporter-Staff News Editor at Clinical Trials Week -- Data detailed on Biomedicine have been presented. According to news reporting from New York City, New York, by NewsRx journalists, research stated, "CD19-targeted chimeric antigen receptor (CAR) T cells are currently being tested in the clinic with very promising outcomes. However, limitations to CART cell therapy exist."

The news correspondents obtained a quote from the research from Molecular Pharmacology and Chemistry Program, "These include lack of efficacy against some tumors, specific targeting of tumor cells without affecting normal tissue and retaining activity within the suppressive tumor microenvironment. Whereas promising clinical trials are in progress, preclinical development is focused on optimizing CAR design, to generate 'armored CART cells,' which are protected from the inhibitory tumor microenvironment. Studies investigating the expression of cytokine transgenes, combination therapy with small molecule inhibitors, or monoclonal antibodies, are aimed at improving the antitumor efficacy of CART cell therapy. Other strategies aimed at improving CART cell therapy include using dual CARs and chemokine receptors to more specifically target tumor cells."

According to the news reporters, the research concluded: "This review will describe the current clinical data and some novel armored CAR T cell approaches for improving antitumor efficacy therapy."

For more information on this research see: CD28z CARs and Armored CARs. Cancer Journal, 2014;20(2):127-133. Cancer Journal can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA (see also Biomedicine).

Our news journalists report that additional information may be obtained by contacting H.J. Pegram, Mem Sloan Kettering Canc Center, Mol Pharmacol & Chem Program, New York, NY 10065, United States. Additional authors for this research include J.H. Park and R.J. Brentjens.

Keywords for this news article include: Biotechnology, Biomedicine, Cell Therapy, New York City, United States, Biological Therapy, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Clinical Trials Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters